Rothschild & Co Redburn analyst Issie Kirby raised the firm’s price target on Tandem Diabetes (TNDM) to $45 from $36 and keeps a Buy rating on the shares, offering over 125% potential upside. The company’s decision to transition to the pharmacy channel “carves a clear path” to profitability and positive free cash flow, the analyst tells investors in a research note. The firm believes Tandem’s relative valuation is yet to adequately reflect its accelerating growth profile and margin potential.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $28 from $25 at TD Cowen
- Leveraging Rx Channel Shift and Mobi Tubeless Launch to Drive Sustainable Growth at Tandem Diabetes Care
- Citi adds ‘upside 90-day catalyst watch’ on Tandem Diabetes
- Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
- Truist upgrades Tandem Diabetes to Buy on growing conviction in upside potential